Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSIn a recent Scientific Reports article titled, “Association of maternal depression and hypothyroidism with infant gastroschisis: a population‑based cohort study in Canada,” the international team led by Dr. Shiliang Liu of the Public Health Agency of Canada with collaborators from the U.S., Malaysia and China, discussed a pioneering population-based cohort study conducted in Canada, where researchers have discovered a significant association between maternal depression and hypothyroidism and an increased risk of infant gastroschisis. The study analyzed data from infants born in Canada from 2004 to 2020.
Gastroschisis, a serious defect where the baby's intestines are outside of the body, has seen a global increase in recent decades. This increase remains unexplained by existing risk factors. The study sought to fill this gap, and the findings could have major implications for understanding the underlying causes and potential prevention strategies.
The researchers used "winter" months and northern areas of residence as indicators of less sunlight and less active lifestyles. They found that infants conceived in winter had a higher rate of gastroschisis (3.4 per 10,000) than those conceived in summer (2.2 per 10,000). The study identified exposure to winter, northern area, hypothyroidism, substance use, tobacco use, and depressive disorders as potential risk factors for gastroschisis.
The study revealed a significant interaction between women under 24 years of age and 2-month conception intervals. Furthermore, the association of maternal depression with infant gastroschisis was mediated by hypothyroidism. In contrast, substance use, hypothyroidism, tobacco smoking, and gestational diabetes showed 5.5-, 3.1-, 2.7-, and 1.2-fold associations, respectively, with maternal depression.
Importantly, the study found that an increased risk of gastroschisis spanned the ten months outside the summer conception interval. This risk was associated with higher levels of stress adaptation, thermoregulation and metabolism, reproduction, and growth effector hormones.
The findings suggest that periconception depression, mediated by hypothyroidism, may play a causal role in offspring gastroschisis. Researchers also found that maternal hypothyroidism could be a key causal factor in the occurrence of many cases of gastroschisis.
The strengths of the study include the use of data from a vast geographical area with differential latitudes and distinctive seasonal variation. However, the study also has several limitations. For instance, some risk factors associated with gastroschisis may be tested after the occurrence of a congenital anomaly or other adverse pregnancy outcomes.
Read the full article here.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.